Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis.

Abstract: A reversion mutation assay that is unique in providing a quantitative readout for mutagenesis. This assay is based on the creation of a functional GFP-?-lactamase fusion protein as a reporter providing both antibiotic resistance and fluorescence. This dual reporter is placed in a multicopy plasmid to increase the number of targets, with a reversion site at the N-terminus. Rare mutations at the reversion site allow read-through of the fusion protein, producing both beta-lactamase (providing antibiotic resistance) and GFP (emitting fluorescence). In the presence of carbenicillin, beta-lactamase production confers a selective advantage that allows amplification of mutant plasmids, raising the level of fluorescence emitted by GFP to levels that are detectable by fluorimetry. A window of time can be found where fluorescence is proportional to the number of mutation events at the reversion site, making fluorescence a quantitative measure of mutagenesis.

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Abstract: Methods for regulating NF-?B activation in cells comprising introducing into the cell a vector comprising a nucleic acid sequence encoding a NIK and IKK2 Binding Protein (NIBP) polypeptide, wherein the NIBP polypeptide is expressed in the cell, are provided. Also provided are methods for reversing the cancerous phenotype of a cancer cell and for modulating neuronal differentiation.

Abstract: Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.

Abstract: The present invention employs three decoupled hardware mechanisms: read and write signatures, which summarize per-thread access sets; per-thread conflict summary tables, which identify the threads with which conflicts have occurred; and a lazy versioning mechanism, which maintains the speculative updates in the local cache and employs a thread-private buffer (in virtual memory) only in the rare event of an overflow. The conflict summary tables allow lazy conflict management to occur locally, with no global arbitration (they also support eager management). All three mechanisms are kept software-accessible, to enable virtualization and to support transactions of arbitrary length.

Abstract: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.

Abstract: The present invention provides metal-free abnormal N-heterocyclic carbenes, also known as imidazol-5-ylidenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of making metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes. The present invention also provides methods of using metal-free abnormal N-heterocyclic carbenes and metal complexes of abnormal N-heterocyclic carbenes in catalytic reactions.

Abstract: Various systems, methods, and programs embodied in computer-readable mediums are provided for fingerprint liveness detection. In one embodiment, a method for determining fingerprint liveness is provided that comprises receiving a plurality of image analysis data of a fingerprint image; condensing the plurality of image analysis data; and determining liveness of the fingerprint image based upon the condensed data.

Abstract: Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer.

Abstract: Novel methods for the production of enantiomerically pure (EP) ?-lactams by decomposition of ?-diazo-?-ketoamides.

Abstract: Various systems, methods, and programs embodied in computer-readable mediums are provided for fingerprint liveness detection. In one embodiment, a method for determining fingerprint liveness is provided that comprises receiving a fingerprint image; extracting a region of interest from the fingerprint image; generating a histogram of the region of interest; determining a statistical feature of the histogram; and determining liveness of the fingerprint image based upon the statistical feature.

Abstract: Various systems, methods, and programs embodied in computer-readable mediums are provided for fingerprint liveness detection. In one embodiment, a method for determining fingerprint liveness is provided that comprises receiving a plurality of image analysis data of a fingerprint image; condensing the plurality of image analysis data; and determining liveness of the fingerprint image based upon the condensed data.

Abstract: The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. The invention also provides methods of identifying inhibitors of tumorigenesis.

Abstract: A system and method for MR magnetic field mapping includes a computer programmed to acquire a first data point at a first location in a first phase image data set, a second data point at the first location in a second phase image data set, a third data point at the first location in a third phase image data set. The first, second, and third phase images are acquired using a first, second, and third TE, respectively. Phase wrapping does not occur among the first and second phase image data sets; however, phase wrapping does occur among the second and third phase image data sets. The computer is also programmed to determine a magnetic field inhomogeneity, wherein the determination of the magnetic field inhomogeneity is based on the first, second, and third data points.

Abstract: We describe modified bacterial cells that are defective in gene expression and their use in the treatment of bacterial infections of animals and plants and the inhibition of bacterial biofilm formation.

Abstract: The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments, the modified Tf molecule has a mutation which decreases the release of bound iron from a Tf complex. The complex can also contain, for instance, a carbonate, oxalate, or other anion to stabilize the Tf iron complex.